Volume 12, Issue 1 (Winter 2024)
Iran J Health Sci 2024, 12(1): 27-38 |
Back to browse issues page
Ethics code: IR.TUMS.IKH.REC.1400.175
Clinical trials code: IR.TUMS.IKH.REC.1400.175
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khalili H, Emadi Koochak H, Salehi M, Dehghan Manshadi S A, Toroghi N, Nourian A, et al . Prevalence of Sputnik V COVID-19 Vaccine Side Effects Among Healthcare Workers in a Tertiary Care, Academic Center in Tehran City, Iran. Iran J Health Sci 2024; 12 (1) :27-38
URL: http://jhs.mazums.ac.ir/article-1-862-en.html
URL: http://jhs.mazums.ac.ir/article-1-862-en.html
Hossein Khalili 
, Hamid Emadi Koochak , Mohammadreza Salehi , Seyed Ali Dehghan Manshadi , Negar Toroghi , Anahid Nourian , Keyhan Mohammadi , Nasim Shirazi , Esmaeil Mohammadnejad , Elnaz Shahmohamadi , Maliheh Hasannezhad *
, Hamid Emadi Koochak , Mohammadreza Salehi , Seyed Ali Dehghan Manshadi , Negar Toroghi , Anahid Nourian , Keyhan Mohammadi , Nasim Shirazi , Esmaeil Mohammadnejad , Elnaz Shahmohamadi , Maliheh Hasannezhad *
Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. , mmalihehasannezhad@yahoo.com
Abstract: (434 Views)
Background and Purpose: COVID-19 vaccine side effects predominantly affect public confidence in vaccination. Therefore, this study evaluated the rate and severity of adverse reactions associated with the COVID-19 Sputnik V vaccine among tertiary healthcare providers in an academic medical center.
Materials and Methods: This retrospective observational study was carried out from March 2021 to August 2021 among Imam Khomeini Hospital Complex healthcare workers, a tertiary referral healthcare center affiliated with Tehran University of Medical Sciences. Participants provided demographic and clinical information through a validated questionnaire after being interviewed. The frequency, severity, and outcome of all reactions after vaccination were recorded. The study utilized SPSS software, version 24.0 to conduct descriptive statistics on baseline variables and inferential statistics to examine associations between vaccine side effects and gender, medical history, and COVID-19 history of the participants. Additionally, ordinal regression analysis was employed to identify factors predicting the severity of adverse effects after the first and second doses of the Sputnik V vaccine.
Results: A total of 372 participants (54.3% female) with a mean age of 36.5±9.18 years were recruited. The rate of at least one side effect was 77.15% and 57.8% after the first and second doses, respectively. The most common side effects among participants were myalgia (48.4% after the first and 28.2% after the second dose), injection site pain (26.3% after the first and 12.6% after the second dose), and fever (19.6% after the first and 12.9% after the second dose). The higher rate of fever and myalgia after the first dose was observed among subjects with a history of COVID-19.
Conclusion: Among healthcare workers, the side effects following the first and second doses of the Sputnik V vaccine were primarily mild, with no cases requiring hospitalization. Further research is required to assess potential side effects in larger and diverse populations with varying demographic and social characteristics.
Materials and Methods: This retrospective observational study was carried out from March 2021 to August 2021 among Imam Khomeini Hospital Complex healthcare workers, a tertiary referral healthcare center affiliated with Tehran University of Medical Sciences. Participants provided demographic and clinical information through a validated questionnaire after being interviewed. The frequency, severity, and outcome of all reactions after vaccination were recorded. The study utilized SPSS software, version 24.0 to conduct descriptive statistics on baseline variables and inferential statistics to examine associations between vaccine side effects and gender, medical history, and COVID-19 history of the participants. Additionally, ordinal regression analysis was employed to identify factors predicting the severity of adverse effects after the first and second doses of the Sputnik V vaccine.
Results: A total of 372 participants (54.3% female) with a mean age of 36.5±9.18 years were recruited. The rate of at least one side effect was 77.15% and 57.8% after the first and second doses, respectively. The most common side effects among participants were myalgia (48.4% after the first and 28.2% after the second dose), injection site pain (26.3% after the first and 12.6% after the second dose), and fever (19.6% after the first and 12.9% after the second dose). The higher rate of fever and myalgia after the first dose was observed among subjects with a history of COVID-19.
Conclusion: Among healthcare workers, the side effects following the first and second doses of the Sputnik V vaccine were primarily mild, with no cases requiring hospitalization. Further research is required to assess potential side effects in larger and diverse populations with varying demographic and social characteristics.
Type of Study: Original Article |
Subject:
Infectious Diseases and Tropical Medicine
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
